Virpax Pharmaceuticals In...

0.28
0.01 (2.98%)
At close: Feb 07, 2025, 3:59 PM
0.28
-0.20%
After-hours Feb 07, 2025, 04:01 PM EST
undefined%
Bid 0.28
Market Cap 5.10M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -7.24
PE Ratio (ttm) -0.04
Forward PE n/a
Analyst Hold
Ask 0.29
Volume 266,980
Avg. Volume (20D) 3,942,476
Open 0.27
Previous Close 0.27
Day's Range 0.27 - 0.30
52-Week Range 0.23 - 5.48
Beta undefined

About VRPX

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an inject...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 17, 2021
Employees 7
Stock Exchange NASDAQ
Ticker Symbol VRPX

Analyst Forecast

According to 3 analyst ratings, the average rating for VRPX stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 978.55% from the latest price.

Buy 0.00%
Hold 33.33%
Sell 0.00%
Stock Forecasts
1 week ago
+6.12%
Virpax Pharmaceuticals shares are trading lower af... Unlock content with Pro Subscription
2 months ago
-3.85%
Virpax shares are trading higher after the company announced results from the swine model dose range finding study for Probudur.